ArticleMolecular oral microbiology2020
Epigallocatechin gallate inhibits leukotoxin release by Aggregatibacter actinomycetemcomitans by promoting association with the bacterial membrane.
Article in Molecular oral microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Antimicrobial and anti-biofilm activity of Epigallocatechin gallate against Vibrio parahaemolyticus.NPJ science of food · 2026Article
- Chrysin and Luteolin from Moroccan Propolis to Prevent Aggressive Periodontitis Caused byPharmaceuticals (Basel, Switzerland) · 2026Article
- A Review of the Impact of Green Tea (Current pharmaceutical design · 2026Review
- Effects of Green Tea Extract Epigallocatechin-3-Gallate on Oral Diseases: A Narrative Review.Pathogens (Basel, Switzerland) · 2024Review
- Bacteria-derived extracellular vesicles: endogenous roles, therapeutic potentials and their biomimetics for the treatment and prevention of sepsis.Frontiers in immunology · 2024Review
- Aggregatibacter actinomycetemcomitans: From Basic to Advanced Research.Advances in experimental medicine and biology · 2022Article
- Inhibitors of Bacterial Extracellular Vesicles.Frontiers in microbiology · 2022Review
- Effects of green tea extract epigallocatechin-3-gallate (EGCG) on oral disease-associated microbes: a review.Journal of oral microbiology · 2022Review
- Nanoarrays of Individual Liposomes and Bacterial Outer Membrane Vesicles by Liftoff Nanocontact Printing.Small (Weinheim an der Bergstrasse, Germany) · 2021Article
- Applications of Catechins in the Treatment of Bacterial Infections.Pathogens (Basel, Switzerland) · 2021Review
- Prevalence of JP2 and Non-JP2 Genotypes ofPathogens (Basel, Switzerland) · 2021Article
- Size Exclusion Chromatography to Analyze Bacterial Outer Membrane Vesicle Heterogeneity.Journal of visualized experiments : JoVE · 2021Article
- Epigallocatechin gallate alters leukotoxin secretion and Aggregatibacter actinomycetemcomitans virulence.The Journal of pharmacy and pharmacology · 2021Article
- Interactions of Tea-Derived Catechin Gallates with Bacterial Pathogens.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The oral pathogen, Aggregatibacter actinomycetemcomitans, produces a number of virulence factors, including a leukotoxin (LtxA), which specifically kills human white blood cells, to provide a colonization advantage to the bacterium. Strains of A. actinomycetemcomitans that produce more LtxA have been more closely linked to disease, indicating that this toxin plays a key role in pathogenesis of the bacterium. Disruption of the activity of LtxA thus represents a promising approach to reducing the pathogenicity of the bacterium. Catechins are polyphenolic molecules derived from plants, which have shown potent antibacterial and antitoxin activities. We have previously shown that galloylated catechins are able to prevent LtxA delivery to host cells by altering the toxin's secondary structure and preventing binding to cholesterol on the host cell membrane. Here, we have investigated how one particular galloylated catechin, epigallocatechin gallate (EGCg), affects A. actinomycetemcomitans growth and toxin secretion. Our results demonstrate that EGCg, at micromolar concentrations, inhibits A. actinomycetemcomitans growth, as has been reported for other bacterial species. At subinhibitory concentrations, EGCg promotes LtxA production, but the toxicity of the bacterial supernatant against human immune cells is reduced. The results of our biophysical studies indicate that this seemingly contradictory result is caused by an EGCg-mediated enhancement of LtxA affinity for the bacterial cell surface. Together, these results demonstrate the potential of EGCg in the treatment of virulent A. actinomycetemcomitans infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.